Core Insights - The company, Deep Intelligent Pharma (DIP), focuses on AI-enabled clinical development for new drugs and has recently completed a $40 million financing round to enhance its operations and market reach [1][2]. Company Overview - Deep Intelligent Pharma was established on September 22, 2017, and is headquartered in Beijing, positioning itself as a provider of AI technology services specifically for the entire process of new drug clinical development and application [2]. Products and Technology - The company's core offerings include: - An automated clinical trial protocol design and writing system that covers I-III phase clinical trial protocols, informed consent forms, and investigator brochures [5]. - A full-cycle document automation tool for clinical trials, which includes processing clinical research reports, safety reports, and protocol amendments [7]. - An intelligent platform for new drug application documentation, utilizing a multi-agent AI system that integrates "AI bionic brain + expert" models to cover preclinical research, registration, clinical trials, and post-marketing studies [6]. Financing History - Recent financing milestones include: - December 2025: Completed a $50 million D round financing led by Dinghui Baifu, with participation from New Ding Capital and Sequoia China [8]. - February 2026: Secured $60 million in financing from investors including Xincheng Capital and others, with existing shareholders increasing their stakes [8]. - March 2026: Finalized a $40 million financing round with collective participation from existing shareholders [1][8].